[go: up one dir, main page]

Isomorphic Labs Limited[1] is a London-based company which uses artificial intelligence for drug discovery.[2][3][4] Isomorphic Labs was founded by Demis Hassabis, who also serves as the CEO.[5][3] The company was incorporated on February 24, 2021[1] and announced on November 4, 2021.[6] It was established under Alphabet Inc. as a spin-off from its AI research lab DeepMind, of which Hassabis is also founder and CEO.[2][3][7]

Isomorphic Labs Limited
Company typeSubsidiary
IndustryDrug discovery
Founded24 February 2021 Edit this on Wikidata
FounderDemis Hassabis
HeadquartersLondon, United Kingdom
Key people
  • Demis Hassabis (CEO)
  • Pamela Carroll (COO)
  • Miles Congreve (CSO)
  • Max Jaderberg (CAIO)
  • Sergei Yakneen (CTO)
ParentAlphabet Inc.
Websiteisomorphiclabs.com

The company draws upon DeepMind's AlphaFold technology, which can be used to predict protein structures in the human body with high accuracy, allowing its researchers to find new target pathways for drug delivery.[7][8]

In December 2022, Isomorphic Labs announced its second office location in Lausanne, Switzerland.[7][9]

In January 2024, Isomorphic Labs partnered with Novartis AG and Eli Lilly and Company to work together on AI drug discovery and research.[10]

In May 2024, Google DeepMind and Isomorphic Labs announced the release of AlphaFold 3, freely available on the AlphaFold server for non-commercial research. AlphaFold 3 is not limited to predicting how proteins fold, it can also predict the interactions with molecules typically found in drugs such as ligands or antibodies, which is expected to significantly accelerate drug discovery.[11]

References

edit
  1. ^ a b "ISOMORPHIC LABS LIMITED overview - Find and update company information - GOV.UK". Companies House. February 24, 2021. Retrieved August 20, 2023.
  2. ^ a b Shead, Sam (November 5, 2021). "Google-parent Alphabet has set up a new lab that will use A.I. to try to discover new drugs". CNBC. Archived from the original on November 5, 2021. Retrieved November 9, 2021.
  3. ^ a b c Coldewey, Devin (November 4, 2021). "Isomorphic Labs is Alphabet's play in AI drug discovery". TechCrunch. Retrieved August 23, 2022.
  4. ^ Crist, Ry (November 4, 2021). "Alphabet launches Isomorphic Labs, an AI-driven drug discovery startup". CNET.
  5. ^ Shead, Sam (November 5, 2021). "Google-parent Alphabet has set up a new lab that will use A.I. to try to discover new drugs". CNBC. Retrieved November 30, 2023.
  6. ^ Wetsman, Nicole (November 4, 2021). "Alphabet is launching a company that uses AI for drug discovery". The Verge. Retrieved September 22, 2024.
  7. ^ a b c Criddle, Cristina; Johnston, Ian (December 3, 2022). "DeepMind spin-off steps up effort to use AI to create new drugs". Financial Times. Archived from the original on December 5, 2022. Retrieved April 28, 2023.
  8. ^ Quach, Katyanna (November 8, 2021). "Alphabet launches new AI drug discovery startup, Isomorphic Labs, led by DeepMind CEO". The Register. Archived from the original on November 27, 2022. Retrieved April 28, 2023.
  9. ^ Aaron Hurst (December 5, 2022). "DeepMind spin-off Isomorphic Labs announces drug discovery scale plans". Information Age.
  10. ^ Barton, Samantha (January 8, 2024). "Alphabet's Isomorphic Labs to collaborate with Novartis, Lilly on AI-driven drug discovery". Fortune.
  11. ^ Thomason, James (May 8, 2024). "Google's AlphaFold 3 AI predicts the very building blocks of life". VentureBeat. Retrieved May 9, 2024.
edit